阿奇霉素序贯法治疗小儿肺炎支原体肺炎的效果及安全性

摘要

Objective:To evaluate the efficacy and safety of Mycoplasma pneumoniae pneumonia with azithromycin sequential therapy. Method:80 cases of Mycoplasma pneumoniae pneumonia from Jan 2011 to Dec 2013 admitted to our hospital were randomly divided into observation group(n=40) and control group(n=40),observation group was given azithromycin sequential therapy,control group was given erythromycin sequential therapy,observed and compared the efficacy and adverse events of two groups.Result:The total effective rate of observation group was 95.0%,control group was 85.0%,the difference was statistically significant(P<0.05);The rash,abnormal liver function,local pain,elevated transaminases and gastrointestinal road reactions adverse drug reactions of observation group were lower than control group,the differences were statistically significant(P<0.05).Conclusion:Mycoplasma pneumoniae pneumonia with azithromycin sequential therapy is effective,safe,to be worthy of promotion in clinical practice.%目的：评价阿奇霉素序贯法治疗小儿肺炎支原体肺炎的有效性及安全性。方法：选取2011-2013年笔者所在医院收治的80例小儿肺炎支原体肺炎患儿，随机分为两组，其中观察组40例采用阿奇霉素序贯法治疗，对照组40例采用红霉素序贯法治疗，观察并比较两组的临床疗效及不良反应发生情况。结果：观察组总有效率为95.0%，对照组为85.0%，差异有统计学意义(P<0.05)；观察组患儿的皮疹、肝功能异常、局部疼痛、转氨酶升高及胃肠道反应等药物不良反应发生率均低于对照组，差异有统计学意义(P<0.05)。结论：阿奇霉素序贯法治疗小儿肺炎支原体肺炎疗效好，安全性高，值得在临床上予以推广。